

=> d his

(FILE 'HOME' ENTERED AT 14:50:33 ON 09 SEP 2005)

FILE 'REGISTRY' ENTERED AT 14:50:43 ON 09 SEP 2005

L1 STRUCTURE UPLOADED
L2 0 S L1 SSS
L3 0 S L1 SSS FULL
L4 STRUCTURE UPLOADED *Chm 1*
L5 0 S L4 SSS
L6 5 S L4 SSS FULL
L7 STRUCTURE UPLOADED *Chm 2*
L8 0 S L7 SSS
L9 1 S L7 SSS FULL
L10 STRUCTURE UPLOADED *Chm 3*
L11 0 S L10 SSS
L12 1 S L10 SSS FULL
L13 STRUCTURE UPLOADED *Chm 6*
L14 0 S L13 SSS
L15 5 S L13 SSS FULL

FILE 'CAPLUS' ENTERED AT 15:01:49 ON 09 SEP 2005

L16 2 S L6 OR L9 OR L12 OR L15

=> d l1

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> d bib abs hitstr 1-2

L16 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:550750 CAPLUS

DN 141:87914

TI Antibiotics Cyan-416A, Cyan-416B, Cyan-416C, Cyan-416D, and Cyan-416E, and ester derivatives of Cyan-416B

IN He, Haiyin; Bigelis, Ramunas

PA Wyeth Holdings Corporation, USA

SO U.S. Pat. Appl. Publ., 30 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	US 2004132812	A1	20040708	US 2003-736425	20031215
PRAI	US 2002-434004P	P	20021217		
OS	MARPAT 141:87914				

AB The invention relates to new antibiotics designated Cyan-416A, Cyan 416B, Cyan-416C, Cyan-416D and Cyan-416E to their production by fermentation of Acremonium

sp. NRRL 30631 to methods for recovery and concentration from the crude solns.,

and to a process for purification and to semisynthetic ethers of Cyan-416B.

IT 701914-77-4P, Cyan 416A

RL: BMF (Bioindustrial manufacture); BSU (Biological study, unclassified);

CPS (Chemical process); PEP (Physical, engineering or chemical process);

PRP (Properties); PUR (Purification or recovery); RCT (Reactant); BIOL

(Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent)


(antibiotics cyan-416A, cyan-416B, cyan-416C, cyan-416D, and cyan-416E, and ester derivs. of cyan-416B)

RN 701914-77-4 CAPLUS

CN Benzoic acid, 2-[[(5aR,6S,13S)-6-(acetyloxy)-5,6,12,13-tetrahydro-1,3,10,11-tetrahydroxy-8-methyl-12-oxo-5a,13-etheno-5aH-benzo[4,5]cyclohepta[1,2-b]naphthalen-2-yl]carbonyl]-3,6-dihydroxy-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Currently available stereo shown.



IT 701914-78-5DP, Cyan 416B, and esters of

RL: BSU (Biological study, unclassified); CPS (Chemical process); IMF (Industrial manufacture); PEP (Physical, engineering or chemical process); PRP (Properties); PUR (Purification or recovery); RCT (Reactant); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent)


(antibiotics cyan-416A, cyan-416B, cyan-416C, cyan-416D, and cyan-416E, and ester derivs. of cyan-416B)

RN 701914-78-5 CAPLUS

CN Benzoic acid, 3,6-dihydroxy-2-[[(5aR,6S,13S)-5,6,12,13-tetrahydro-1,3,6,10,11-pentahydroxy-8-methyl-12-oxo-5a,13-etheno-5aH-benzo[4,5]cyclohepta[1,2-b]naphthalen-2-yl]carbonyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Currently available stereo shown.



IT 701914-82-1P, Cyan 416B butyrate 701914-83-2P, Cyan 416B

isobutyrate 701914-84-3P, Cyan 416B pentanoate

701914-85-4P, Cyan 416B hexanoate

RL: IMF (Industrial manufacture); PREP (Preparation)

(antibiotics cyan-416A, cyan-416B, cyan-416C, cyan-416D, and cyan-416E,


and ester derivs. of cyan-416B)

RN 701914-82-1 CAPLUS

CN Benzoic acid, 3,6-dihydroxy-2-[[(5aR,6S,13S)-5,6,12,13-tetrahydro-1,3,10,11-tetrahydroxy-8-methyl-12-oxo-6-(1-oxobutoxy)-5a,13-etheno-5aH-benzo[4,5]cyclohepta[1,2-b]naphthalen-2-yl]carbonyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Currently available stereo shown.




RN 701914-83-2 CAPLUS

CN Benzoic acid, 3,6-dihydroxy-2-[[(5aR,6S,13S)-5,6,12,13-tetrahydro-1,3,10,11-tetrahydroxy-8-methyl-6-(2-methyl-1-oxopropoxy)-12-oxo-5a,13-etheno-5aH-benzo[4,5]cyclohepta[1,2-b]naphthalen-2-yl]carbonyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Currently available stereo shown.




RN 701914-84-3 CAPLUS

CN Benzoic acid, 3,6-dihydroxy-2-[[(5aR,6S,13S)-5,6,12,13-tetrahydro-1,3,10,11-tetrahydroxy-8-methyl-12-oxo-6-[(1-oxopentyl)oxy]-5a,13-etheno-5aH-benzo[4,5]cyclohepta[1,2-b]naphthalen-2-yl]carbonyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


Currently available stereo shown.



RN 701914-85-4 CAPLUS

CN Benzoic acid, 3,6-dihydroxy-2-[[[(5aR,6S,13S)-5,6,12,13-tetrahydro-1,3,10,11-tetrahydroxy-8-methyl-12-oxo-6-[(1-oxohexyl)oxy]-5a,13-etheno-5aH-benzo[4,5]cyclohepta[1,2-b]naphthalen-2-yl]carbonyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Currently available stereo shown.



L16 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:949247 CAPLUS

DN 141:36024

TI Acremonidins, new polyketide-derived antibiotics produced by Acremonium sp., LL-Cyan 416

AU He, Haiyin; Bigelis, Ramunas; Solum, Eric H.; Greenstein, Michael; Carter, Guy T.

CS Natural Products Research, Chemical and Screening Sciences, Wyeth Research, Pearl River, NY, 10965, USA

SO Journal of Antibiotics (2003), 56(11), 923-930
CODEN: JANTAJ; ISSN: 0021-8820

PB Japan Antibiotics Research Association

DT Journal

LA English

AB Acremonidins A, B and acremonidins C, D were produced by fermentation of Acremonium sp., LL-Cyan 416, in heterogeneous phases. The structures of these compds., containing a bridging keto group, were determined by spectroscopic

anal. Acremonidins A and Acremonidins B showed moderate activity against Gram-pos. bacteria, including the methicillin-resistant staphylococci and vancomycin-resistant enterococci. Acremonidins C, Acremonidins D, and acremonidin C were also active against Gram-pos. bacteria. Selective acylations of Acremonidins B afforded ester derivs. that exhibited improved antibacterial activity.

IT 701914-78-5P, Acremonidin B


RL: BMF (Bioindustrial manufacture); NPO (Natural product occurrence); PAC (Pharmacological activity); PRP (Properties); PUR (Purification or recovery); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(acremonidins are new polyketide-derived antibiotics produced by Acremonium LL-Cyan 416)

RN 701914-78-5 CAPLUS

CN Benzoic acid, 3,6-dihydroxy-2-[[(5aR,6S,13S)-5,6,12,13-tetrahydro-1,3,6,10,11-pentahydroxy-8-methyl-12-oxo-5a,13-etheno-5aH-benzo[4,5]cyclohepta[1,2-b]naphthalen-2-yl]carbonyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Currently available stereo shown.



IT 701914-77-4P, Acremonidin A


RL: BMF (Bioindustrial manufacture); NPO (Natural product occurrence); PAC (Pharmacological activity); PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses)

(acremonidins are new polyketide-derived antibiotics produced by Acremonium LL-Cyan 416)

RN 701914-77-4 CAPLUS

CN Benzoic acid, 2-[[(5aR,6S,13S)-6-(acetyloxy)-5,6,12,13-tetrahydro-1,3,10,11-tetrahydroxy-8-methyl-12-oxo-5a,13-etheno-5aH-benzo[4,5]cyclohepta[1,2-b]naphthalen-2-yl]carbonyl]-3,6-dihydroxy-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Currently available stereo shown.



IT 701914-82-1P, Acremonidin B butyrate 701914-83-2P,
Acremonidin B isobutyrate 701914-84-3P, Acremonidin B pentanoate
701914-85-4P, Acremonidin B hexanoate


RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and antibacterial activity of)

RN 701914-82-1 CAPLUS

CN Benzoic acid, 3,6-dihydroxy-2-[[(5aR,6S,13S)-5,6,12,13-tetrahydro-1,3,10,11-tetrahydroxy-8-methyl-12-oxo-6-(1-oxobutoxy)-5a,13-etheno-5aH-benzo[4,5]cyclohepta[1,2-b]naphthalen-2-yl]carbonyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Currently available stereo shown.



RN 701914-83-2 CAPLUS

CN Benzoic acid, 3,6-dihydroxy-2-[[(5aR,6S,13S)-5,6,12,13-tetrahydro-1,3,10,11-tetrahydroxy-8-methyl-6-(2-methyl-1-oxopropoxy)-12-oxo-5a,13-etheno-5aH-benzo[4,5]cyclohepta[1,2-b]naphthalen-2-yl]carbonyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Currently available stereo shown.



RN 701914-84-3 CAPLUS

CN Benzoic acid, 3,6-dihydroxy-2-[[(5aR,6S,13S)-5,6,12,13-tetrahydro-1,3,10,11-tetrahydroxy-8-methyl-12-oxo-6-[(1-oxopentyl)oxy]-5a,13-etheno-5aH-benzo[4,5]cyclohepta[1,2-b]naphthalen-2-yl]carbonyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Currently available stereo shown.



RN 701914-85-4 CAPLUS

CN Benzoic acid, 3,6-dihydroxy-2-[[(5aR,6S,13S)-5,6,12,13-tetrahydro-1,3,10,11-tetrahydroxy-8-methyl-12-oxo-6-[(1-oxohexyl)oxy]-5a,13-etheno-5aH-benzo[4,5]cyclohepta[1,2-b]naphthalen-2-yl]carbonyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Currently available stereo shown.



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>